Core Insights - Zentek Ltd. has announced that its subsidiary, Albany Graphite Corp., achieved near theoretical anode performance in independent lithium-ion battery testing using ultrahigh purity Albany graphite [1] Company Summary - Zentek Ltd. operates in the lithium-ion battery sector through its subsidiary, Albany Graphite Corp., focusing on high-performance materials [1] - The achievement of near theoretical anode performance indicates significant advancements in the company's product capabilities, potentially enhancing its competitive position in the battery materials market [1]

Group 1 - Zentek Ltd. has appointed Mohammed (Moe) Jiwan as the new Chief Executive Officer and a director, effective December 1, 2025 [1]

Core Points - Zentek Ltd. has received a notice of reassessment from the Canada Revenue Agency regarding its 2019 financial year related to the Flow-Through Financings [1] - The Flow-Through Financings were completed on December 21, 2018, and December 20, 2019, with aggregate gross proceeds of $4,210,000 [1] Financial Impact - The reassessment pertains to the Canadian exploration expenses renunciations for the years 2018 and 2019 [1]

Core Insights - Zentek Ltd. has developed a novel Graphite Gel-Based Fire-Retardant (GBFR) product aimed at protecting homes from wildfires through rapid gelation and intumescent components [1] Company Overview - Zentek Ltd. is an intellectual property technology development and commercialization company [1] - The company is listed on Nasdaq under the ticker ZTEK and on TSX-V under the ticker ZEN [1] Product Development - The new GBFR product combines rapid gelation with intumescent properties to enhance wildfire protection for residential structures [1]

Core Viewpoint - Zentek Ltd. has successfully closed a non-brokered private placement of units, raising gross proceeds of $2,479,227 through the issuance of 2,338,893 units at a price of $1.06 per unit [1][2]. Group 1: Offering Details - Each unit consists of one common share, one-half of a Series A warrant, and one-half of a Series B warrant [2]. - The Series A warrant allows the holder to purchase one common share at $1.50 until October 22, 2027, with potential acceleration of the expiry date if the share price reaches $2.00 for 10 consecutive trading days [3]. - The Series B warrant allows the holder to purchase one common share at $2.00 until October 22, 2028, with potential acceleration if the share price reaches $3.00 for 10 consecutive trading days [4]. Group 2: Financial Aspects - The company paid finder fees totaling $35,429.33 and issued finder warrants for the purchase of 33,424 units at $1.06 per unit until October 22, 2027 [5]. - Proceeds from the offering will be utilized for general and administrative corporate purposes [6]. Group 3: Company Background - Zentek is an intellectual property development and commercialization company focused on enhancing product safety and efficiency through innovative technologies [11]. - The company’s patented ZenGUARD™ technology improves viral filtration efficiency for surgical masks and HVAC systems, with production facilities located in Guelph, Ontario [12].

Core Points - Zentek Ltd. has announced an increase in its non-brokered private placement to a total of up to $2,500,000, allowing for the issuance of up to 2,358,490 Units at a price of $1.06 per Unit [1] - The proceeds from the Offering will be utilized for working capital and general corporate purposes [1] Summary by Sections Offering Details - Each Unit consists of one Common Share, one-half of a Series A Warrant, and one-half of a Series B Warrant [2] - Series A Warrants allow the purchase of one Common Share at $1.50 for 24 months, with potential acceleration if the share price reaches $2.00 for 10 consecutive trading days [3] - Series B Warrants allow the purchase of one Common Share at $2.00 for 36 months, with potential acceleration if the share price reaches $3.00 for 10 consecutive trading days [4] Regulatory and Compliance - The closing of the Offering is subject to necessary corporate and regulatory approvals, including TSXV approval [5] - All securities issued will be subject to a hold period of four months plus a day from the date of issuance [5] Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of innovative products [7] - The company's patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8] - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University for diagnostic and therapeutic markets [10]

Core Insights - Zentek Ltd. is an intellectual property technology development and commercialization company that has provided an update regarding its subsidiary Albany Graphite Corp. on activities funded by the Critical Minerals Innovation Fund [1] Group 1 - The update follows a previous release dated September 22, 2025, indicating ongoing developments in the company's initiatives [1]

Core Viewpoint - Zentek Ltd. announces a non-brokered private placement to raise up to $2,000,000 through the issuance of units priced at $1.06 each, aimed at funding working capital and general corporate purposes [1]. Group 1: Private Placement Details - The offering will consist of up to 1,886,792 units, each unit comprising one common share, one-half of a Series A warrant, and one-half of a Series B warrant [2]. - Series A warrants allow the purchase of one common share at $1.50 for 24 months, with potential acceleration if the share price exceeds $2.00 for 10 consecutive trading days [3]. - Series B warrants permit the purchase of one common share at $2.00 for 36 months, with acceleration possible if the share price exceeds $3.00 for 10 consecutive trading days [4]. Group 2: Regulatory and Approval Information - The closing of the offering is contingent upon receiving necessary corporate and regulatory approvals, including from the TSX Venture Exchange [5]. - All securities issued will be subject to a four-month hold period from the date of issuance [5]. Group 3: Stock Options and Restricted Share Units - The company has granted stock options to certain officers, directors, and employees to acquire a total of 979,000 common shares at $1.06 per share, with a vesting schedule over five years [7]. - Additionally, 779,000 restricted share units have been granted, vesting on October 1, 2026 [7]. Group 4: Company Overview - Zentek is an intellectual property development and commercialization company focused on creating novel products that enhance the safety and efficiency of commercial partners' offerings [8][9]. - The company holds a global exclusive license for an Aptamer-based platform technology developed by McMaster University, targeting diagnostic and therapeutic markets [10].

Core Insights - Zentek Ltd. is an intellectual property technology development and commercialization company that has provided an update regarding its subsidiary Albany Graphite Corp. on activities funded by the Critical Minerals Innovation Fund [1] Group 1 - The update highlights the progress made by Albany Graphite Corp. in relation to its grant-funded activities [1]

Core Viewpoint - Zentek Ltd. has successfully completed the first in vivo tests of its lead candidate countermeasure for seasonal influenza (H1N1) as part of the Innovative Solutions Canada Testing Stream [1] Company Summary - Zentek Ltd. is listed on Nasdaq under the ticker ZTEK and on TSX-V under the ticker ZEN [1]